View Supplier Profile Jan 30 2020
Although the three-dimensional (3-D) shape of erythrocytes is strongly associated with various malignant blood disorders, conventional optical imaging approaches only provide information on two-dimensional morphology.
Now, a Korean research team has used the Tomocube holotomography microscope to observe uniquely shaped red blood cells (RBCs) for the first time in the peripheral blood of a patient diagnosed with myelodysplastic syndrome (MDS) (1) .
This could be a breakthrough for the rapid diagnosis of MDS, a group of cancers that disrupt the production and maturation of blood cells within the bone marrow. Not only may it eliminate the need to carry out a confirmatory bone marrow examination under local anaesthetic but the ability to quickly screen blood samples may help with early diagnosis of MDS, a disease that progresses to acute myeloid leukaemia (AML) in approximately one third of patients.” Aubrey lambert, Tomocube’s Chief Marketing Officer
The research team was led by Dr. Seongsoo Jang of the University of Ulsan College of Medicine and Asan Medical Center in Seoul, Korea. Using blood samples left over from the complete blood cell count of a patient originally diagnosed with MDS who had subsequently undergone an allogeneic hematopoietic stem cell transplantation (HSCT), the 3-D RI tomograms of reconstructed RBCs revealed unique cup-shaped RBCs in approx. one-third of the RBCs.
No cup-shaped RBCs were found in a control sample and the normal 2-D light microscopy examination was unable to differentiate between normal and cup-shaped RBCs.
The myelodysplastic syndromes (MDS) are a group of fast-progressing diseases affecting the elderly in which most of the immature blood cells in the bone marrow are of poor quality and are destroyed before they leave the bone marrow. Related Stories
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology